Market
Outcome of PTC518 Phase 2 Trials by End of 2024?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%
Clinical trial results published by PTC Therapeutics or Novartis
Story
PTC Therapeutics Secures $2.9B Deal with Novartis for Huntington's Drug, $1B Upfront
Dec 2, 2024, 01:09 PM
PTC Therapeutics Inc. has entered into a significant licensing agreement with Novartis AG, focusing on the development of PTC518, an experimental drug for Huntington's disease. The deal, which could be worth up to $2.9 billion, includes an upfront payment of $1 billion to PTC Therapeutics. Under the terms, Novartis will share U.S. profits and losses with PTC Therapeutics on a 40/60 basis, with PTC receiving 40%. This collaboration marks Novartis's renewed interest in Huntington's disease treatments. The agreement also involves global licensing and collaboration for the drug's development, with Novartis taking the lead in further development efforts.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
Three or more • 25%
Two • 25%
One • 25%
None • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Other outcome • 25%
Positive results leading to Phase 2 • 25%
Neutral results requiring further study • 25%
Negative results halting development • 25%
Progressive Disease • 25%
Stable Disease • 25%
Complete Response • 25%
Partial Response • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Moderate improvement • 25%
Worsening condition • 25%
No improvement • 25%
